anonymous
Guest
anonymous
Guest
I am seeing a lot of posts & comments on Pfizer's boards about Gilead launching their JAK and Xeljanz reps already having personal interviews this week.
I ve been w Gilead 11 yrs and let me share the FACTS with you as some on your company posts are true and others a little off.
FIRST: Gilead is one of the Top Biotechs in the world w cash in the bank and revenues. We made our mark in the HIV/AIDS, Hepatology, & Oncology markets. Now we are going full force into our 4th area as our new CEO outlined--Immunology which will end up being the biggest revenue producing business unit of the 4.
Yes we are launching a small sales force of 90-105 reps to sell JAK for RA & Crohns w 8 other indications, however we are NOT creating this Immunology Division just for the JAK.
The JAK is the 1st of a very strong & deep Phase 3 & 2 Immunology pipeline with state of the art new class of drugs including Genetic Medicine/Treatment.
The latter is the reason we are creating the Immunology division. The JAK is just a product to get 5-8% share but more importantly start to establish relationships w Rhuems GIs & Immunologists for the blockbuster agents coming out in 2yrs.
Last year Gilead bought 30% of Galapagos biotech who is heavy into Immunology & Genetic Compounds . The 30% ownership gives Gilead all the current and future compounds & pipeline worldwide outside of Europe. (Similar to Pfizer & Amgen w Enbrel)
*** Pfizer is not even in the same league w RD & pipeline as Gilead-- especially with I&I. We are high science.
SECOND: Things must be really bad w Xeljanz because 17 Xeljanz DMs posted on our website but given our criteria we only personally interviewed 11. (More than the Gilead will have so it is extremely selective w success, experience and business strategy skills sets. We do not want just 1 or 2 yr flash in pan success)
What is more astonishing now that we starting interviewing reps the last 2 wks, we had almost 100 Xeljanz Reps post on our website which blew our recruiters away and we had to hire vendors to help phone interview.
Again given our strict criteria only half of those have been selected for personal interviews that started in some areas of the country 2 wks ago.
THIRD: Rep Total Comp that I ve read on your site is pretty accurate . Yearly 250k+ which for reps is industry leading, not 50%tile like Pfizer.
The KEY however is our yearly company Stock Awards 35k + a year for Sr reps and can go up. Some of the top performing reps got 60k Stock last year BUT ALL REPS GET STOCK. Not just top 20% like Pfizer which is just really 4-5k in RSU Stock value.
Just 100% Stock alone is an 500k to 1 million or more in 12yrs- and that is if the stock doesnt grow. When it grows, easily could be over million more.
So with even a lateral in base, a REP will be potentially million dollars wealthier with company Stock vs staying at Pfizer.
(And the managers/DM level, we pay total compensation that is higher than what Pfizer pays their 2nd line Directors who report to the VP...... )
SUMMARY: Do not believe your managers talking down about Gilead due to the 4th JAK as this is not the reason we are creating our Immunology division. In the meantime we will launch our JAK with a small Salesforce's of 1 rep territories calling on just select customers with realistic 2SE/2IR goals. NOT to beat Humira.
Very realistic goals and win the 2SE position.
Our goal is to bring a highly efficacious ACR70 agent with good side effect profile to the patients while building relationships for our blockbusters of 5-6 different Immunology compounds starting in 2yrs.
So if you were one of the good Xeljanz reps who are listening to the wrong information , you might want to call the recruiter back to get into the live interview pool that is ongoing.
THERE YOU HAVE 100% FACTS FROM A Q1YR VET. ANYTHING ELSE SAID BY PFIZER OR OTHER POSTS ARE NOT TRUE AND SIMPLE ATTEMPTS TO RETAIN THE 100 REPS WHO POSTED.
(FYI we will probably only hire 20 of you anyway as we look for specific elements of success and business skills at Gilead )
I ve been w Gilead 11 yrs and let me share the FACTS with you as some on your company posts are true and others a little off.
FIRST: Gilead is one of the Top Biotechs in the world w cash in the bank and revenues. We made our mark in the HIV/AIDS, Hepatology, & Oncology markets. Now we are going full force into our 4th area as our new CEO outlined--Immunology which will end up being the biggest revenue producing business unit of the 4.
Yes we are launching a small sales force of 90-105 reps to sell JAK for RA & Crohns w 8 other indications, however we are NOT creating this Immunology Division just for the JAK.
The JAK is the 1st of a very strong & deep Phase 3 & 2 Immunology pipeline with state of the art new class of drugs including Genetic Medicine/Treatment.
The latter is the reason we are creating the Immunology division. The JAK is just a product to get 5-8% share but more importantly start to establish relationships w Rhuems GIs & Immunologists for the blockbuster agents coming out in 2yrs.
Last year Gilead bought 30% of Galapagos biotech who is heavy into Immunology & Genetic Compounds . The 30% ownership gives Gilead all the current and future compounds & pipeline worldwide outside of Europe. (Similar to Pfizer & Amgen w Enbrel)
*** Pfizer is not even in the same league w RD & pipeline as Gilead-- especially with I&I. We are high science.
SECOND: Things must be really bad w Xeljanz because 17 Xeljanz DMs posted on our website but given our criteria we only personally interviewed 11. (More than the Gilead will have so it is extremely selective w success, experience and business strategy skills sets. We do not want just 1 or 2 yr flash in pan success)
What is more astonishing now that we starting interviewing reps the last 2 wks, we had almost 100 Xeljanz Reps post on our website which blew our recruiters away and we had to hire vendors to help phone interview.
Again given our strict criteria only half of those have been selected for personal interviews that started in some areas of the country 2 wks ago.
THIRD: Rep Total Comp that I ve read on your site is pretty accurate . Yearly 250k+ which for reps is industry leading, not 50%tile like Pfizer.
The KEY however is our yearly company Stock Awards 35k + a year for Sr reps and can go up. Some of the top performing reps got 60k Stock last year BUT ALL REPS GET STOCK. Not just top 20% like Pfizer which is just really 4-5k in RSU Stock value.
Just 100% Stock alone is an 500k to 1 million or more in 12yrs- and that is if the stock doesnt grow. When it grows, easily could be over million more.
So with even a lateral in base, a REP will be potentially million dollars wealthier with company Stock vs staying at Pfizer.
(And the managers/DM level, we pay total compensation that is higher than what Pfizer pays their 2nd line Directors who report to the VP...... )
SUMMARY: Do not believe your managers talking down about Gilead due to the 4th JAK as this is not the reason we are creating our Immunology division. In the meantime we will launch our JAK with a small Salesforce's of 1 rep territories calling on just select customers with realistic 2SE/2IR goals. NOT to beat Humira.
Very realistic goals and win the 2SE position.
Our goal is to bring a highly efficacious ACR70 agent with good side effect profile to the patients while building relationships for our blockbusters of 5-6 different Immunology compounds starting in 2yrs.
So if you were one of the good Xeljanz reps who are listening to the wrong information , you might want to call the recruiter back to get into the live interview pool that is ongoing.
THERE YOU HAVE 100% FACTS FROM A Q1YR VET. ANYTHING ELSE SAID BY PFIZER OR OTHER POSTS ARE NOT TRUE AND SIMPLE ATTEMPTS TO RETAIN THE 100 REPS WHO POSTED.
(FYI we will probably only hire 20 of you anyway as we look for specific elements of success and business skills at Gilead )